Figure A1.

Secondary analysis of the percentage of patients with an anti–epidermal growth factor receptor (EGFR) agent use before last claim submission: This analysis calculated the percentage of patients who were treated with an anti-EGFR agent in the past, out of the number of patients who had their last claim submitted in a given 2-month interval. The following equation was used: [number of patients treated with an anti-EGFR agent in second-line or beyond] ÷ [number of patients having their last claim filed in a given 2-month period]. FDA, US Food and Drug Administration.